Kevin Tang's Concentra Biosciences lines up deal for flailing cancer cell therapy company Cargo Therapeutics — potentially ...

Hong Kong billionaire Richard Li’s insurer FWD Group saw its shares close flat in the company’s long-awaited Hong Kong stock ...

The digital health market is welcoming new IPOs for the first time in years. Bankers and investors think these 9 startups ...

Broader macroeconomic uncertainty has resulted in continued cautiousness for both investors and acquirers in the in vitro ...

Baystreet.ca News Commentary – As populations age and chronic illnesses become more widespread, healthcare systems around the world are being pushed to their limits. But a ...

Initial public offerings (IPOs) just keep on coming in 2025 and they continue to remain in heavy demand. Companies have already raised about $25.4 billion through IPOs so far this year, exceeding the ...

Caris Life Sciences applies AI and machine learning to patient samples to detect cancer and as a companion diagnostic guiding the use of targeted cancer therapies. As a commercial-stage company ...

Caris Life Sciences is experiencing rapid growth, leveraging AI and molecular science for personalized medicine. Click here to find out why CAI stock is a Hold.

Despite raising the price of its IPO twice, Caris Life Sciences Inc. left money on the table with a 33% increase in price as soon as trading commenced on the Nasdaq, though no one is squawking about ...

Cancer-testing company Caris Life Sciences surged in its stock-market debut Wednesday, continuing a run of strong initial public offerings for revenue-making healthcare companies.

The successful IPO of Caris Life Sciences makes its founder David Dean Halbert worth an estimated $3.3 billion.

Caris Life Sciences spikes by over 30% in IPO debut, embraces AI as future of oncology In an interview, the company’s president said cancer doctors need not be afraid of machine learning.